

Peter E Clark

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6226961/publications.pdf>

Version: 2024-02-01

256
papers

10,112
citations

29994

54
h-index

45213

90
g-index

264
all docs

264
docs citations

264
times ranked

11439
citing authors

#	ARTICLE	IF	CITATIONS
1	Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. <i>Circulation</i> , 2010, 121, 833-840.	1.6	312
2	Bladder Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 446-475.	2.3	309
3	Oncologic Efficacy of CT-Guided Percutaneous Radiofrequency Ablation of Renal Cell Carcinomas. <i>American Journal of Roentgenology</i> , 2007, 189, 429-436.	1.0	282
4	A Comparison of the Incidence and Location of Positive Surgical Margins in Robotic Assisted Laparoscopic Radical Prostatectomy and Open Retropubic Radical Prostatectomy. <i>Journal of Urology</i> , 2007, 178, 2385-2390.	0.2	255
5	Early and Late Perioperative Outcomes Following Radical Cystectomy: 90-Day Readmissions, Morbidity and Mortality in a Contemporary Series. <i>Journal of Urology</i> , 2010, 184, 1296-1300.	0.2	226
6	ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers. <i>European Urology</i> , 2013, 63, 4-15.	0.9	225
7	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1240-1267.	2.3	220
8	Effect of Preoperative Nutritional Deficiency on Mortality After Radical Cystectomy for Bladder Cancer. <i>Journal of Urology</i> , 2011, 185, 90-96.	0.2	212
9	Radical cystectomy in the elderly. <i>Cancer</i> , 2005, 104, 36-43.	2.0	193
10	Contemporary Open Radical Cystectomy: Analysis of Perioperative Outcomes. <i>Journal of Urology</i> , 2008, 179, 1313-1318.	0.2	193
11	Percutaneous CT-Guided Radiofrequency Ablation of Renal Neoplasms: Factors Influencing Success. <i>American Journal of Roentgenology</i> , 2004, 183, 201-207.	1.0	182
12	URETHRAL TUMOR RECURRENCE FOLLOWING CYSTECTOMY AND URINARY DIVERSION: CLINICAL AND PATHOLOGICAL CHARACTERISTICS IN 768 MALE PATIENTS. <i>Journal of Urology</i> , 2005, 173, 1163-1168.	0.2	176
13	The ADPRT V762A Genetic Variant Contributes to Prostate Cancer Susceptibility and Deficient Enzyme Function. <i>Cancer Research</i> , 2004, 64, 6344-6348.	0.4	159
14	Penile Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 594-615.	2.3	149
15	Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 194-201.	157.7	148
16	Preoperative Nutritional Status Is an Important Predictor of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma. <i>European Urology</i> , 2011, 59, 923-928.	0.9	146
17	Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: impact of the amount of remaining renal tissue. <i>Urology</i> , 2001, 57, 252-256.	0.5	134
18	Robotic Assisted Laparoscopic Prostatectomy Versus Radical Retropubic Prostatectomy for Clinically Localized Prostate Cancer: Comparison of Short-Term Biochemical Recurrence-Free Survival. <i>Journal of Urology</i> , 2010, 183, 990-996.	0.2	131

#	ARTICLE	IF	CITATIONS
19	13-YEAR EXPERIENCE WITH PERCUTANEOUS MANAGEMENT OF UPPER TRACT TRANSITIONAL CELL CARCINOMA. <i>Journal of Urology</i> , 1999, 161, 772-776.	0.2	115
20	Renal cell cancer histological subtype distribution differs by race and sex. <i>BJU International</i> , 2016, 117, 260-265.	1.3	115
21	Ureteroenteric Anastomotic Strictures After Radical Cystectomyâ€”Does Operative Approach Matter?. <i>Journal of Urology</i> , 2013, 189, 541-547.	0.2	113
22	Renal cell carcinomaâ€™derived gangliosides suppress nuclear factor-Î² activation in T cells. <i>Journal of Clinical Investigation</i> , 1999, 104, 769-776.	3.9	110
23	National Trends in the Use of Partial Nephrectomy: A Rising Tide That Has Not Lifted All Boats. <i>Journal of Urology</i> , 2012, 187, 816-821.	0.2	109
24	Association of Procedure Volume With Radical Cystectomy Outcomes in a Nationwide Database. <i>Journal of Urology</i> , 2007, 178, 1418-1422.	0.2	106
25	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. <i>Nature Communications</i> , 2017, 8, 15724.	5.8	106
26	Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. <i>Urology</i> , 2001, 57, 281-285.	0.5	103
27	The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. <i>Kidney International</i> , 2009, 76, 939-945.	2.6	100
28	NF-Î² Gene Signature Predicts Prostate Cancer Progression. <i>Cancer Research</i> , 2014, 74, 2763-2772.	0.4	99
29	Predicting the Probability of 90-Day Survival of Elderly Patients With Bladder Cancer Treated With Radical Cystectomy. <i>Journal of Urology</i> , 2011, 186, 829-834.	0.2	97
30	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1213-1224.	2.3	93
31	Airway bacteria drive a progressive COPD-like phenotype in mice with polymeric immunoglobulin receptor deficiency. <i>Nature Communications</i> , 2016, 7, 11240.	5.8	91
32	Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. <i>Urology</i> , 2006, 67, 1257-1261.	0.5	90
33	Original Articles: Testis Cancer: A Review of Scrotal Violation in Testicular Cancer: Is Adjuvant Local Therapy Necessary?. <i>Journal of Urology</i> , 1995, 153, 981-985.	0.2	87
34	THE MANAGEMENT OF URETHRAL TRANSITIONAL CELL CARCINOMA AFTER RADICAL CYSTECTOMY FOR INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2004, 172, 1342-1347.	0.2	86
35	The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 871-877.	0.8	86
36	Loss of the Urothelial Differentiation Marker FOXA1 Is Associated with High Grade, Late Stage Bladder Cancer and Increased Tumor Proliferation. <i>PLoS ONE</i> , 2012, 7, e36669.	1.1	81

#	ARTICLE	IF	CITATIONS
37	Serum Methionine Metabolites Are Risk Factors for Metastatic Prostate Cancer Progression. PLoS ONE, 2011, 6, e22486.	1.1	80
38	Alterations in NFĀB Activation in T Lymphocytes of Patients With Renal Cell Carcinoma. Journal of the National Cancer Institute, 1999, 91, 718-721.	3.0	78
39	Microwave Ablation of Renal Parenchymal Tumors Before Nephrectomy: Phase I Study. American Journal of Roentgenology, 2007, 188, 1212-1214.	1.0	75
40	Tumor-derived Mutations in the TRAIL Receptor DR5 Inhibit TRAIL Signaling through the DR4 Receptor by Competing for Ligand Binding. Journal of Biological Chemistry, 2007, 282, 28189-28194.	1.6	70
41	Salvage Robotic Assisted Laparoscopic Radical Prostatectomy: A Single Institution, 5-Year Experience. Journal of Urology, 2013, 189, 507-513.	0.2	70
42	Comparison of transfusion requirements between open and roboticĀssisted laparoscopic radical prostatectomy. BJU International, 2010, 106, 1036-1040.	1.3	68
43	Incidence and predictors of understaging in patients with clinical <scp>T</scp>1 urothelial carcinoma undergoing radical cystectomy. BJU International, 2014, 113, 894-899.	1.3	67
44	Microscopic and Gross Extravesical Extension in Pathological Staging of Bladder Cancer. Journal of Urology, 2004, 171, 640-645.	0.2	61
45	Radical cystectomy in the elderly. Cancer, 2005, 103, 546-552.	2.0	61
46	Voiding Function in Women with Orthotopic Neobladder Urinary Diversion. Journal of Urology, 2012, 188, 200-204.	0.2	61
47	Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. American Journal of Pathology, 2015, 185, 1385-1395.	1.9	60
48	CT-Guided Biopsy for the Diagnosis of Renal Tumors Before Treatment with Percutaneous Ablation. American Journal of Roentgenology, 2007, 188, 1500-1505.	1.0	59
49	Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis, 2007, 29, 573-578.	1.3	59
50	Determining Factors for Hospital Discharge Status After Radical Cystectomy in a Large Contemporary Cohort. Journal of Urology, 2011, 185, 85-89.	0.2	59
51	The influence of obesity-related factors in the etiology of renal cell carcinomaĀA mendelian randomization study. PLoS Medicine, 2019, 16, e1002724.	3.9	59
52	Bladder Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 8-39.	2.3	58
53	Intake of Plant Foods and Associated Nutrients in Prostate Cancer Risk. Nutrition and Cancer, 2009, 61, 216-224.	0.9	57
54	Volume Outcomes of CystectomyĀIs it the Surgeon or the Setting?. Journal of Urology, 2012, 188, 2139-2144.	0.2	57

#	ARTICLE	IF	CITATIONS
55	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	57
56	Utility of frozen section analysis of resection margins during partial nephrectomy. <i>Urology</i> , 2004, 64, 31-34.	0.5	56
57	Impaired Activation of NF κ B in T Cells From a Subset of Renal Cell Carcinoma Patients Is Mediated by Inhibition of Phosphorylation and Degradation of the Inhibitor, I κ B α . <i>Blood</i> , 1998, 92, 1334-1341.	0.6	55
58	Bladder cancer. <i>Current Opinion in Oncology</i> , 2008, 20, 307-314.	1.1	55
59	The Impact of Health Literacy on Surgical Outcomes Following Radical Cystectomy. <i>Journal of Health Communication</i> , 2016, 21, 99-104.	1.2	55
60	Cytokine genetic polymorphisms and prostate cancer aggressiveness. <i>Carcinogenesis</i> , 2009, 30, 1358-1362.	1.3	53
61	Prostate Size as a Predictor of Gleason Score Upgrading in Patients With Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2011, 186, 2221-2227.	0.2	53
62	Dosimetric quantifiers for low-dose-rate prostate brachytherapy: Is V100 superior to D90?. <i>Brachytherapy</i> , 2005, 4, 252-258.	0.2	51
63	Chemokine Markers Predict Biochemical Recurrence of Prostate Cancer following Prostatectomy. <i>Clinical Cancer Research</i> , 2008, 14, 7790-7797.	3.2	51
64	Masculinity and the Body: How African American and White Men Experience Cancer Screening Exams Involving the Rectum. <i>American Journal of Men's Health</i> , 2009, 3, 300-309.	0.7	51
65	Preoperative Hydronephrosis Predicts Extravesical and Node Positive Disease in Patients Undergoing Cystectomy for Bladder Cancer. <i>Journal of Urology</i> , 2010, 183, 1732-1737.	0.2	50
66	Blocking TGF- β 2 and β 2-Catenin Epithelial Crosstalk Exacerbates CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3490-3503.	3.0	50
67	Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. <i>Molecular Cancer Research</i> , 2003, 1, 385-92.	1.5	50
68	Natural history of surgically treated bladder carcinoma with extravesical tumor extension. <i>Cancer</i> , 2003, 98, 955-961.	2.0	49
69	Smaller Prostate Size Predicts High Grade Prostate Cancer at Final Pathology. <i>Journal of Urology</i> , 2010, 184, 930-937.	0.2	49
70	NF κ B and androgen receptor variant expression correlate with human BPH progression. <i>Prostate</i> , 2016, 76, 491-511.	1.2	49
71	Impact of Positive Apical Surgical Margins on Likelihood of Biochemical Recurrence After Radical Prostatectomy. <i>Journal of Urology</i> , 2009, 182, 2695-2701.	0.2	48
72	Bladder cancer. <i>Current Opinion in Oncology</i> , 2009, 21, 272-277.	1.1	48

#	ARTICLE	IF	CITATIONS
73	ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. <i>BJU International</i> , 2012, 110, E641-6.	1.3	47
74	Men's knowledge and beliefs about prostate cancer: education, race, and screening status. <i>Ethnicity and Disease</i> , 2009, 19, 199-203.	1.0	47
75	Bladder cancer. <i>Current Opinion in Oncology</i> , 2003, 15, 227-233.	1.1	45
76	DNA damage levels in prostate cancer cases and controls. <i>Carcinogenesis</i> , 2006, 27, 1187-1193.	1.3	45
77	Pathological Stage T2 Subgroups to Predict Biochemical Recurrence After Prostatectomy. <i>Journal of Urology</i> , 2009, 182, 2291-2295.	0.2	44
78	Lymph Node Yield at Radical Cystectomy Predicts Mortality in Node-negative and not Node-positive Patients. <i>Urology</i> , 2012, 80, 632-640.	0.5	44
79	Urinary Diversion Trends at a High Volume, Single American Tertiary Care Center. <i>Journal of Urology</i> , 2009, 182, 2369-2375.	0.2	43
80	Anatomic Basis for Lymph Node Counts as Measure of Lymph Node Dissection Extent: A Cadaveric Study. <i>Urology</i> , 2013, 81, 358-363.	0.5	43
81	Does Inflammation Mediate the Obesity and BPH Relationship? An Epidemiologic Analysis of Body Composition and Inflammatory Markers in Blood, Urine, and Prostate Tissue, and the Relationship with Prostate Enlargement and Lower Urinary Tract Symptoms. <i>PLoS ONE</i> , 2016, 11, e0156918.	1.1	43
82	Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUDâ€“SIU joint consultation on bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 3-13.	1.2	42
83	PPAR γ : A molecular link between systemic metabolic disease and benign prostate hyperplasia. <i>Differentiation</i> , 2011, 82, 220-236.	1.0	41
84	Bladder cancer. <i>Current Opinion in Oncology</i> , 2011, 23, 275-282.	1.1	40
85	Imaging the Clear Cell Renal Cell Carcinoma Proteome. <i>Journal of Urology</i> , 2013, 189, 1097-1103.	0.2	40
86	The von Hippel-Lindau gene. <i>Cancer</i> , 2008, 113, 1768-1778.	2.0	39
87	Infant communicating hydrocelesâ€”do they need immediate repair or might some clinically resolve?. <i>Journal of Pediatric Surgery</i> , 2010, 45, 590-593.	0.8	39
88	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 747-754.	0.9	39
89	Higher Incidence of Hemorrhagic Cystitis Following Haploidentical Related Donor Transplantation Compared with Matched Related Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 785-790.	2.0	38
90	Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP α transcription factor network. <i>Prostate</i> , 2014, 74, 669-679.	1.2	37

#	ARTICLE	IF	CITATIONS
91	Effect of a large prostate gland on open and robotically assisted laparoscopic radical prostatectomy. <i>BJU International</i> , 2008, 101, 1140-1144.	1.3	36
92	Management of superficial and muscle-invasive urothelial cancers of the bladder. <i>Current Opinion in Oncology</i> , 2013, 25, 281-288.	1.1	36
93	When urothelial differentiation pathways go wrong: Implications for bladder cancer development and progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 802-811.	0.8	33
94	Waiting Time From Initial Urological Consultation to Nephrectomy for Renal Cell Carcinoma—Does it Affect Survival?. <i>Journal of Urology</i> , 2008, 179, 2152-2157.	0.2	32
95	Bladder cancer. <i>Current Opinion in Oncology</i> , 2010, 22, 242-249.	1.1	32
96	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. <i>European Urology</i> , 2020, 78, 316-320.	0.9	32
97	Impact of Comorbidity on Survival of Invasive Bladder Cancer Patients, 1996-2007: A Danish Population-based Cohort Study. <i>Urology</i> , 2010, 75, 393-398.	0.5	31
98	Bladder cancer. <i>Current Opinion in Oncology</i> , 2005, 17, 275-280.	1.1	30
99	On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer. <i>Nature Reviews Urology</i> , 2017, 14, 98-106.	1.9	30
100	Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 299.e19-299.e25.	0.8	30
101	Complementary and Alternative Medicine for Advanced Prostate Cancer. <i>Urologic Clinics of North America</i> , 2006, 33, 237-246.	0.8	29
102	Î2-Catenin and K-RAS Synergize to Form Primitive Renal Epithelial Tumors with Features of Epithelial Wilms' Tumors. <i>American Journal of Pathology</i> , 2011, 179, 3045-3055.	1.9	29
103	Men's Knowledge and Beliefs About Colorectal Cancer and 3 Screenings: Education, Race, and Screening Status. <i>American Journal of Health Behavior</i> , 2011, 35, 525-34.	0.6	29
104	Association between physical activity, lower urinary tract symptoms (<scp>LUTS</scp>) and prostate volume. <i>BJU International</i> , 2013, 111, 122-128.	1.3	29
105	Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. <i>BJU International</i> , 2015, 116, 351-357.	1.3	29
106	Tumour size, tumour complexity, and surgical approach are associated with nephrectomy type in small renal cortical tumours treated electively. <i>BJU International</i> , 2012, 109, 1607-1613.	1.3	28
107	Short term complications from transurethral resection of bladder tumor. <i>Canadian Journal of Urology</i> , 2016, 23, 8198-203.	0.0	28
108	Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: Analysis of patient outcomes. <i>Cancer</i> , 2009, 115, 770-775.	2.0	27

#	ARTICLE	IF	CITATIONS
109	Biochemical Recurrence-free Survival After Robotic-assisted Laparoscopic vs Open Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer. <i>Urology</i> , 2014, 83, 1309-1315.	0.5	27
110	Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia. <i>Endocrinology</i> , 2016, 157, 1094-1109.	1.4	27
111	Sex specific associations in genome wide association analysis of renal cell carcinoma. <i>European Journal of Human Genetics</i> , 2019, 27, 1589-1598.	1.4	27
112	A Simple, Effective Method to Create Laparoscopic Renal Protective Hypothermia With Cold Saline Surface Irrigation: Clinical Application and Assessment. <i>Journal of Urology</i> , 2010, 184, 1861-1866.	0.2	26
113	Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 21.e11-21.e17.	0.8	25
114	Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. <i>Urology</i> , 2004, 63, 1061-1065.	0.5	24
115	Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 29-44.	1.7	24
116	Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. <i>Urology</i> , 2006, 67, 349-353.	0.5	23
117	Oncologic Outcomes after Anterior Exenteration for Muscle Invasive Bladder Cancer in Women. <i>Journal of Urology</i> , 2016, 196, 1030-1035.	0.2	23
118	Prostate Cancer and Bone Metastases: Medical Treatment. <i>Clinical Orthopaedics and Related Research</i> , 2003, 415, S148-S157.	0.7	22
119	Radical nephrectomy surgical outcomes in the University HealthSystem Consortium Data Base. <i>Cancer</i> , 2009, 115, 2447-2452.	2.0	22
120	Current Concepts in Penile Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 617-624.	2.3	22
121	Genetic and chromosomal alterations in K enyan W ilms T umor. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 702-715.	1.5	22
122	NF- κ B and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. <i>Prostate</i> , 2016, 76, 1004-1018.	1.2	22
123	Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. <i>Molecular Oncology</i> , 2017, 11, 405-421.	2.1	22
124	Management changes for patients with endocrine-related cancers in the COVID-19 pandemic. <i>Endocrine-Related Cancer</i> , 2020, 27, R357-R374.	1.6	22
125	Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. <i>Oncotarget</i> , 2017, 8, 722-741.	0.8	22
126	Urinary Collecting System Invasion Is a Predictor for Overall and Disease-specific Survival in Locally Invasive Renal Cell Carcinoma. <i>Urology</i> , 2011, 78, 99-104.	0.5	21

#	ARTICLE	IF	CITATIONS
127	Prognostic factors in T3b renal cell carcinoma. <i>World Journal of Urology</i> , 2009, 27, 75-79.	1.2	20
128	Comparison of American Joint Committee on Cancer Pathological Stage T2a Versus T2b Urothelial Carcinoma: Analysis of Patient Outcomes in Organ Confined Bladder Cancer. <i>Journal of Urology</i> , 2009, 181, 540-546.	0.2	20
129	Lack of P16 ^{ink4a} Over Expression in Penile Squamous Cell Carcinoma is Associated with Recurrence after Lymph Node Dissection. <i>Journal of Urology</i> , 2015, 193, 519-525.	0.2	20
130	Angiomyolipoma with vena caval extension. <i>Urology</i> , 2002, 60, 695-696.	0.5	19
131	Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 821-830.	1.1	19
132	Comparative Analysis of Whole Mount Processing and Systematic Sampling of Radical Prostatectomy Specimens: Pathological Outcomes and Risk of Biochemical Recurrence. <i>Journal of Urology</i> , 2010, 184, 1334-1340.	0.2	19
133	Impact of Complications and Hospital-Free Days on Health Related Quality of Life 1 Year after Radical Cystectomy. <i>Journal of Urology</i> , 2014, 192, 1360-1364.	0.2	19
134	Contemporary Management of the Urethra in Patients After Radical Cystectomy for Bladder Cancer. <i>Urologic Clinics of North America</i> , 2005, 32, 199-206.	0.8	18
135	Inflammatory myofibroblastic tumor associated with renal cell carcinoma. <i>Urology</i> , 2005, 66, 880.e7-880.e9.	0.5	18
136	Recent advances in targeted therapy for renal cell carcinoma. <i>Current Opinion in Urology</i> , 2007, 17, 331-336.	0.9	18
137	Bladder cancer. <i>Current Opinion in Oncology</i> , 2007, 19, 241-247.	1.1	18
138	Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 196-200.	0.8	18
139	Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. <i>BJU International</i> , 2009, 104, 1091-1097.	1.3	18
140	Long-term Use of Statins and Risk of Renal Cell Carcinoma: A Population-based Case-Control Study. <i>European Urology</i> , 2016, 69, 877-882.	0.9	18
141	MAGI-2 in prostate cancer: an immunohistochemical study. <i>Human Pathology</i> , 2016, 52, 83-91.	1.1	18
142	The Androgen Receptor CAG Repeat and Prostate Cancer Risk. , 2003, 81, 255-266.		17
143	Assessing Retroperitoneal Lymphadenectomy Experience in United States Urological Residency Programs. <i>Journal of Urology</i> , 2007, 178, 500-503.	0.2	17
144	Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells <i>In Vitro</i> . <i>Molecular Cancer Therapeutics</i> , 2021, 20, 398-409.	1.9	17

#	ARTICLE	IF	CITATIONS
145	Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: A tale of two methods. <i>World Journal of Urology</i> , 2011, 29, 15-20.	1.2	16
146	Blood loss associated with radical cystectomy: A prospective, randomized study comparing Impact LigaSure vs. stapling device. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 45.e11-45.e15.	0.8	16
147	TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 286-293.	0.8	16
148	Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. <i>Cancer</i> , 2006, 107, 1093-1100.	2.0	15
149	Immediate surgical outcomes for radical prostatectomy in the University HealthSystem Consortium Clinical Data Base: the impact of hospital case volume, hospital size and geographical region on 48â€f000 patients. <i>BJU International</i> , 2009, 104, 1442-1445.	1.3	15
150	Recovery of Urinary Function After Radical Prostatectomy: Identification of Trajectory Cluster Groups. <i>Journal of Urology</i> , 2012, 187, 1346-1351.	0.2	15
151	A Murine Model of K-RAS and β -Catenin Induced Renal Tumors Expresses High Levels of E2F1 and Resembles Human Wilms Tumor. <i>Journal of Urology</i> , 2015, 194, 1762-1770.	0.2	15
152	Bladder cancer. <i>Current Opinion in Oncology</i> , 2004, 16, 257-262.	1.1	14
153	Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. <i>BJU International</i> , 2009, 104, 934-937.	1.3	14
154	Intraoperative Registration for Image-Guided Kidney Surgery. <i>IEEE/ASME Transactions on Mechatronics</i> , 2010, 15, 847-852.	3.7	14
155	Trends in kidney cancer among the elderly in Denmark, 1980â€“2012. <i>Acta OncolÃ³gica</i> , 2016, 55, 79-84.	0.8	14
156	Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 258.e1-258.e6.	0.8	14
157	Bladder cancer. <i>Current Opinion in Oncology</i> , 2006, 18, 277-283.	1.1	13
158	TRAIL and Interferon- γ Act Synergistically to Induce Renal Cell Carcinoma Apoptosis. <i>Journal of Urology</i> , 2010, 184, 1166-1174.	0.2	13
159	F 2 -Isoprostanes as a Biomarker of Oxidative Stress in the Mouse Bladder. <i>Journal of Urology</i> , 2014, 191, 1597-1601.	0.2	13
160	Management of noninvasive bladder cancers. <i>Current Opinion in Oncology</i> , 2015, 27, 185-190.	1.1	13
161	MAGI2 is an independent predictor of biochemical recurrence in prostate cancer. <i>Prostate</i> , 2018, 78, 616-622.	1.2	13
162	Urinary diversion after radical cystectomy. <i>Current Treatment Options in Oncology</i> , 2002, 3, 389-402.	1.3	12

#	ARTICLE	IF	CITATIONS
163	Neovesical-urethral anastomotic stricture after orthotopic urinary diversion: presentation and management. <i>BJU International</i> , 2008, 101, 219-222.	1.3	12
164	Sigmoid-urachal-cutaneous Fistula in an Adult Male. <i>Urology</i> , 2009, 73, 444.e5-444.e7.	0.5	12
165	MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma. <i>American Journal of Clinical Pathology</i> , 2016, 146, 294-302.	0.4	12
166	Intermediate-Term Outcome with Radical Prostatectomy for Localized Prostate Cancer: The Cleveland Clinic Experience. <i>Prostate Journal</i> , 2001, 3, 118-125.	0.2	11
167	Core Needle Biopsy and Fine Needle Aspiration Alone or in Combination: Diagnostic Accuracy and Impact on Management of Renal Masses. <i>Journal of Urology</i> , 2017, 197, 1396-1402.	0.2	10
168	Pharmacologic Inhibition of β -Catenin With Pyrvinium Inhibits Murine and Human Models of Wilms Tumor. <i>Oncology Research</i> , 2017, 25, 1653-1664.	0.6	10
169	Urothelial carcinoma with squamous differentiation: Response to chemotherapy and radiation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 434-436.	0.8	9
170	Open renal biopsy: comorbidities and complications in a contemporary series. <i>BJU International</i> , 2009, 106, 102-106.	1.3	8
171	EXOPHYTIC NONINVASIVE GROWTH PATTERN OF RENAL ANGIOMYOLIPOMAS: : IMPLICATIONS FOR NEPHRON SPARING SURGERY. <i>Journal of Urology</i> , 2001, 165, 513-514.	0.2	7
172	Renal Peripheral Neuroectodermal Tumor Presenting at Age 78: Case Report. <i>Scientific World Journal</i> , The, 2008, 8, 830-834.	0.8	7
173	Assessing the Surgical Skills of Urology Residents After Preurology General Surgery Training: The Surgical Skills Learning Needs of New Urology Residents. <i>Journal of Surgical Education</i> , 2011, 68, 341-346.	1.2	7
174	Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder. <i>Current Opinion in Oncology</i> , 2012, 24, 278-283.	1.1	7
175	Comprehensive handbook for developing a bladder cancer cystectomy database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 812-826.	0.8	7
176	Increased nuclear factor I/B expression in prostate cancer correlates with AR expression. <i>Prostate</i> , 2020, 80, 1058-1070.	1.2	7
177	Radiofrequency ablation of renal tumors. <i>Current Urology Reports</i> , 2004, 5, 39-44.	1.0	6
178	National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3346-3348.	0.8	6
179	Epidemiology and survival outcome of adult kidney, bladder, and prostate rhabdomyosarcoma: A SEER database analysis. <i>Rare Tumors</i> , 2020, 12, 203636132097740.	0.3	6
180	Safety of decreasing ureteral stent duration following radical cystectomy. <i>World Journal of Urology</i> , 2021, 39, 473-479.	1.2	6

#	ARTICLE	IF	CITATIONS
181	Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity. <i>Human Pathology</i> , 2021, 107, 96-103.	1.1	6
182	Endourologic Management of Upper Tract Transitional Cell Carcinoma. <i>Scientific World Journal</i> , The, 2004, 4, 62-75.	0.8	6
183	A Rare Case of an Extra-Adrenal Myelolipoma Arising in the Renal Sinus: A Case Report and Review of the Literature. <i>Scientific World Journal</i> , The, 2005, 5, 109-117.	0.8	5
184	Restaging Transurethral Resection for Non-Muscle Invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2013, 40, 295-304.	0.8	5
185	Progress made in the use of animal models for the study of high-risk, nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2014, 24, 512-516.	0.9	5
186	High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 900-906.	0.8	5
187	Implementation of a Dedicated Enhanced Recovery after Surgery (ERAS) Program for Radical Cystectomy Patients is Associated With Decreased Postoperative Inpatient Opioid Usage and Pain Scores. <i>Urology</i> , 2020, 143, 186-193.	0.5	5
188	Racial Disparities in Prostate Specific Antigen Screening and Referral to Urology in a Large, Integrated Health Care System: A Retrospective Cohort Study. <i>Journal of Urology</i> , 2021, 206, 270-278.	0.2	5
189	Prognostic significance of clinicopathologic and deoxyribonucleic acid flow cytometric variables in non-metastatic renal cell carcinoma in the modern era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 328-332.	0.8	4
190	A Simple Model Predicts Freedom From Biochemical Recurrence After Low-Dose Rate Prostate Brachytherapy Alone. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 199-204.	0.6	4
191	Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone. <i>Brachytherapy</i> , 2008, 7, 286-289.	0.2	4
192	GRade, Age, Nodes, and Tumor (GRANT) compared with Leibovich score to predict survival in localized renal cell carcinoma: A nationwide study. <i>International Journal of Urology</i> , 2022, 29, 641-645.	0.5	4
193	Novel Simulation Model of Non-Muscle Invasive Bladder Cancer: A Platform for a Virtual Randomized Trial of Conservative Therapy vs. Cystectomy in BCG Refractory Patients. <i>Bladder Cancer</i> , 2015, 1, 143-150.	0.2	3
194	Natural biology and management of nonmuscle invasive bladder cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 210-215.	1.1	3
195	Genomic analysis of response to bacillus Calmette-Guèrin (BCG) treatment in high-grade stage 1 bladder cancer patients. <i>Translational Andrology and Urology</i> , 2021, 10, 0-0.	0.6	3
196	Demographic and Socioeconomic Factors Associated with Urinary Stone Disease Management in a Large Urban US Population. <i>Urology</i> , 2021, 153, 93-100.	0.5	3
197	1014: Prospective Dose-Escalation Trial of Lycopene in Men with Recurrent Prostate Cancer Following Definitive Local Therapy. <i>Journal of Urology</i> , 2005, 173, 275-275.	0.2	3
198	Impaired Activation of NF κ B in T Cells From a Subset of Renal Cell Carcinoma Patients Is Mediated by Inhibition of Phosphorylation and Degradation of the Inhibitor, I κ B α . <i>Blood</i> , 1998, 92, 1334-1341.	0.6	3

#	ARTICLE	IF	CITATIONS
199	Clinical outcomes associated with expression of aurora kinase and p53 family members in muscle-invasive bladder cancer. <i>Molecular and Clinical Oncology</i> , 2022, 16, 102.	0.4	3
200	Recent advances in the treatment of bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 1023-1030.	1.1	2
201	Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma. <i>Biologics: Targets and Therapy</i> , 2010, 4, 187.	3.0	2
202	New developments in the management of nonmuscle invasive bladder cancer. <i>Current Opinion in Oncology</i> , 2017, 29, 179-183.	1.1	2
203	Use of venous-thrombotic-embolic prophylaxis in patients undergoing surgery for renal tumors: a questionnaire survey in the Nordic countries (The NORENCA -2 study). <i>Research and Reports in Urology</i> , 2018, Volume 10, 181-187.	0.6	2
204	Safety and effectiveness of percutaneous renal cryoablation with conscious sedation. <i>Arab Journal of Urology Arab Association of Urology</i> , 2020, 18, 163-168.	0.7	2
205	Limited Stage Small Cell Bladder Cancer: Outcomes of a Contemporary Cohort. <i>Bladder Cancer</i> , 2020, 6, 83-90.	0.2	2
206	Differential effect of body mass index by gender on oncological outcomes in patients with renal cell carcinoma. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 420.	0.3	2
207	WAITING TIME FROM DIAGNOSIS TO NEPHRECTOMY FOR RENAL CELL CARCINOMA: DOES IT AFFECT SURVIVAL?. <i>Journal of Urology</i> , 2008, 179, 415-416.	0.2	1
208	A COMPARISON OF AMERICAN JOINT COMMITTEE ON CANCER PATHOLOGIC STAGE T3a VERSUS T3b UROTHELIAL CANCER: ANALYSIS OF PATIENT OUTCOMES. <i>Journal of Urology</i> , 2008, 179, 546-546.	0.2	1
209	1895 PELVIC LYMPH NODE DISSECTION FOR BLADDER CANCER: AN AUTOPSY STUDY. <i>Journal of Urology</i> , 2011, 185, .	0.2	1
210	Comparison and assessment of semi-automatic image segmentation in computed tomography scans for image-guided kidney surgery. <i>Medical Physics</i> , 2011, 38, 6265-6274.	1.6	1
211	127 VOLUME-OUTCOMES IN CYSTECTOMY: IS IT THE SURGEON OR THE SETTING?. <i>Journal of Urology</i> , 2012, 187, .	0.2	1
212	381 SALVAGE ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY A SINGLE INSTITUTION FIVE-YEAR EXPERIENCE. <i>Journal of Urology</i> , 2012, 187, .	0.2	1
213	527 CHANGING UTILIZATION OF NEOADJUVANT AND ADJUVANT CHEMOTHERAPIES FOR MUSCLE-INVASIVE UROTHELIAL CARCINOMA AFTER PUBLICATION OF LANDMARK MANUSCRIPTS. <i>Journal of Urology</i> , 2012, 187, .	0.2	1
214	1586 BLOOD LOSS ASSOCIATED WITH RADICAL CYSTECTOMY A PROSPECTIVE RANDOMIZED STUDY COMPARING IMPACT LIGASURE VERSUS STAPLING DEVICE. <i>Journal of Urology</i> , 2012, 187, .	0.2	1
215	1064 A NOVEL SIMULATION MODEL OF NON-MUSCLE INVASIVE BLADDER CANCER A PLATFORM FOR A VIRTUAL RANDOMIZED TRIAL OF CONSERVATIVE THERAPY VS CYSTECTOMY IN BCG REFRACTORY PATIENTS. <i>Journal of Urology</i> , 2012, 187, .	0.2	1
216	Developments and controversies in the management of noninvasive bladder cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 299-304.	1.1	1

#	ARTICLE	IF	CITATIONS
217	Toward Personalized Guidelines in Bladder Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1458-1460.	2.3	1
218	178: Examining Contemporary Urinary Diversion: A Review of Changing Practice Patterns Diversion Selectivity. Journal of Urology, 2007, 177, 60-60.	0.2	1
219	Comparison of venous thromboembolic complications following urological surgery between patients with or without cancer. Turkish Journal of Urology, 2020, 46, 277-281.	1.3	1
220	Racial and Socioeconomic Disparities in MRI-Fusion Biopsy Utilization to Assess for Prostate Cancer. Urology, 2022, 163, 156-163.	0.5	1
221	Hope and Challenges in the Management of Advanced Renal Cell Carcinoma. Scientific World Journal, The, 2007, 7, 869-869.	0.8	0
222	Upper tract transitional cell carcinoma: Finding a way forward. Cancer, 2007, 110, 1648-1649.	2.0	0
223	RADICAL NEPHRECTOMY SURGICAL OUTCOMES IN THE UNIVERSITY HEALTHSYSTEM CONSORTIUM DATABASE: THE IMPACT OF HOSPITAL CASE VOLUME, HOSPITAL SIZE AND GEOGRAPHIC LOCATION ON 40,000 PATIENTS. Journal of Urology, 2008, 179, 164-164.	0.2	0
224	SURVIVAL OUTCOMES IN PATIENTS UNDERGOING CYTOREDUCTIVE NEPHRECTOMY AS A COMPONENT OF MULTI-MODAL THERAPY FOR RENAL CELL CARCINOMA. Journal of Urology, 2008, 179, 380-380.	0.2	0
225	RISK FACTORS FOR UROTHELIAL CARCINOMA OF THE PROSTATE IN PATIENTS UNDERGOING RADICAL CYSTOPROSTATECTOMY FOR BLADDER CANCER. Journal of Urology, 2008, 179, 532-533.	0.2	0
226	UTILIZATION OF SYSTEMIC THERAPY IN PATIENTS UNDERGOING CYTOREDUCTIVE NEPHRECTOMY AS A COMPONENT OF MULTI-MODAL THERAPY FOR RENAL CELL CARCINOMA. Journal of Urology, 2008, 179, 330-331.	0.2	0
227	A COMPARISON OF AMERICAN JOINT COMMITTEE ON CANCER PATHOLOGIC STAGE T2a VERSUS T2b UROTHELIAL CANCER: ANALYSIS OF PATIENT OUTCOMES IN ORGAN CONFINED BLADDER CANCER. Journal of Urology, 2008, 179, 579-579.	0.2	0
228	THE IMPACT OF COMORBIDITY ON SURVIVAL OF INVASIVE BLADDER CANCER PATIENTS, 1995-2004; A DANISH POPULATION-BASED COHORT STUDY. Journal of Urology, 2008, 179, 532-532.	0.2	0
229	RELATIONSHIP BETWEEN PROSTATE VOLUME AND PATHOLOGIC GRADE OF PROSTATE CANCER. Journal of Urology, 2009, 181, 710.	0.2	0
230	RELATIONSHIP OF URINARY FUNCTION FOLLOWING RADICAL PROSTATECTOMY WITH MEDICAL COMORBIDITIES AND GLOBAL QUALITY OF LIFE PARAMETERS. Journal of Urology, 2009, 181, 89-89.	0.2	0
231	IDENTIFICATION OF DISTINCT OUTCOMES CLUSTERS FOR URINARY FUNCTION FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 2009, 181, 4-4.	0.2	0
232	IMPACT OF POSITIVE APICAL SURGICAL MARGINS (SM) ON THE LIKELIHOOD OF BIOCHEMICAL RECURRENCE (BCR) AFTER PROSTATECTOMY. Journal of Urology, 2009, 181, 668-669.	0.2	0
233	PROGNOSTIC FACTORS IN T3B RENAL CELL CARCINOMA. Journal of Urology, 2009, 181, 494-495.	0.2	0
234	COMPARISON OF 3-YEAR CANCER CONTROL OUTCOMES IN ROBOTIC-ASSISTED LAPAROSCOPIC PROSTATECTOMY (RALP) VERSUS RADICAL RETROPUBIC PROSTATECTOMY (RRP) FOR PROSTATE CANCER. Journal of Urology, 2009, 181, 455-455.	0.2	0

#	ARTICLE	IF	CITATIONS
235	Detection of Tumor Cells in the Bone Offers Independent Prognostic Value in Bladder Cancer Patients: The Clinical and Basic Science Perspective. <i>European Urology</i> , 2011, 60, 239-240.	0.9	0
236	Reply to Sabine Brookman-May, Maximilian Burger, Wolf F. Wieland, and Matthias May's Letter to the Editor re: Todd M. Morgan, Dominic Tang, Kelly L. Stratton, et al. Preoperative Nutritional Status Is an Important Predictor of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma. <i>Eur Urol</i> 2011;59:923â€“8. <i>European Urology</i> , 2011, 60, e47.	0.9	0
237	977 ABO BLOOD TYPE IS AN INDEPENDENT PREDICTOR OF OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
238	434 NOVEL RENAL CELL CARCINOMA BIOMARKER IDENTIFICATION FROM URINARY EXOSOMES. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
239	441 IDENTIFICATION OF A MULTIPLE PEPTIDE SIGNATURE BY IMAGING MASS SPECTROMETRY WHICH ACCURATELY PREDICTS MORTALITY IN RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
240	1803 A PROGNOSTIC MODEL FOR SURVIVAL FOLLOWING CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
241	1226 PERIOPERATIVE COST COMPARISON OF ROBOTIC AND OPEN RADICAL CYSTECTOMY FOR BLADDER CANCER. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
242	1426 CONTEMPORARY MANAGEMENT OF SMALL RENAL MASSES: PARTIAL NEPHRECTOMY IS ASSOCIATED EXCLUSIVELY WITH TUMOR ANATOMIC COMPLEXITY. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
243	1757 USE OF PELVIC LYMPHADENECTOMY IN RADICAL CYSTECTOMY FOR BLADDER CANCER: 10-YEAR EXPERIENCE AT A SINGLE INSTITUTION. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
244	1185 RECOVERY OF URINARY FUNCTION FOLLOWING RADICAL PROSTATECTOMY: IDENTIFICATION OF TRAJECTORY CLUSTER GROUPS. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
245	1900 WORTH A SECOND LOOK: RATES OF UPSTAGING AT THE TIME OF RADICAL CYSTECTOMY AFTER RESTAGING TURBT FOR PERSISTENT T1 UROTHELIAL CARCINOMA. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
246	1763 TREATMENT PATTERNS AND SURVIVAL OUTCOMES OF PATIENTS 50 YEARS OLD AND YOUNGER UNDERGOING DEFINITIVE TREATMENT FOR BLADDER UROTHELIAL CELL CARCINOMA. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
247	Follow-up imaging in the first two years after nephrectomy for T1 RCC: Over-use or necessary care?. <i>Journal of Clinical Urology</i> , 2016, 9, 105-113.	0.1	0
248	Editorial Comment. <i>Journal of Urology</i> , 2018, 199, 1317-1318.	0.2	0
249	Opioid Epidemic and Urology: Effects of Preoperative Opioid Usage on Postoperative Clinical Outcomes in Radical Cystectomy Patients. <i>Journal of the American College of Surgeons</i> , 2019, 229, S318.	0.2	0
250	EDITORIAL COMMENT. <i>Urology</i> , 2020, 142, 131-132.	0.5	0
251	Transversus Abdominis Plane (TAP) Block as a Key Component of a Dedicated Enhanced Recovery after Surgery Program for Nephrectomy Patients. <i>Journal of the American College of Surgeons</i> , 2020, 231, S339-S340.	0.2	0
252	Clinical Utility of Postneoadjuvant Chemotherapy Computerized Tomography for Muscle Invasive Urothelial Bladder Cancer. <i>Urology Practice</i> , 2021, 8, 88-93.	0.2	0

#	ARTICLE	IF	CITATIONS
253	1648: The Influence of Histopathologic Method on Prostatic Carcinoma Incidence and Gleason Grade in Cystoprostatectomy Specimens. Journal of Urology, 2007, 177, 546-547.	0.2	0
254	574: Prospective Assessment of Health Related Quality of Life (HRQOL) at One Year Following Radical Cystectomy and Urinary Diversion. Journal of Urology, 2007, 177, 191-192.	0.2	0
255	Shed alcam as a biomarker for urogenital cancers.. Journal of Clinical Oncology, 2012, 30, 50-50.	0.8	0
256	Surgery for invasive bladder tumors: technique and outcome. Current Opinion in Urology, 1999, 9, 413-418.	0.9	0